Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Adjunctive Pessary Therapy after Emergency Cervical Cerclage for Cervical Insufficiency with Protruding Fetal Membranes in the Second Trimester of Pregnancy: A Novel Modification of Treatment.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
- Publication Information:
Original Publication: New York, NY : Hindawi Pub. Co.
- Subject Terms:
- Abstract:
Aim: To evaluate the effectiveness of adjunctive pessary therapy after emergency cervical cerclage (ECC) in improving perinatal outcome in cervical insufficiency with fetal membranes protruding into the vagina.
Material and Methods: A retrospective analysis of patients treated at the 1st Department of Obstetrics and Gynecology, Medical University of Warsaw, between 2008 and 2013. The study group consisted of 15 women treated with ECC and a pessary and the control group consisted of 17 patients treated with cerclage only.
Results: The mean gestational age at delivery was significantly higher in the study group (34.7 versus 29.7 weeks, p = 0.03). The period between cerclage insertion and delivery was significantly longer in the study group (82.9 versus 52.1 days, p = 0.045). The mean neonatal birthweight and neonatal "discharge alive" ratio were higher in the study group, although not statistically significant (2550 g versus 1883 g, p = 0.14, and 93.3% versus 70.5%, p = 0.18, resp.). NICU hospitalization rates were comparable (33.3% versus 35.3%, p = 0.9).
Conclusions: Adjunctive pessary therapy allows delaying delivery in women treated with ECC due to cervical insufficiency with protruding fetal membranes. It also seems to improve neonatal outcome, although the differences are not statistically significant. Further prospective study is required to prove these findings.
- References:
J Obstet Gynaecol Res. 2014 Feb;40(2):381-6. (PMID: 24147884)
Int J Gynaecol Obstet. 2007 Jan;96(1):16-9. (PMID: 17187796)
J Reprod Med. 2000 Apr;45(4):323-6. (PMID: 10804489)
Am J Perinatol. 1992 May;9(3):142-5. (PMID: 1575830)
Obstet Gynecol. 2006 Feb;107(2 Pt 1):221-6. (PMID: 16449104)
J Obstet Gynaecol Can. 2005 Feb;27(2):123-9. (PMID: 15937588)
Am J Obstet Gynecol. 2005 Mar;192(3):710-8. (PMID: 15746662)
Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):63-7. (PMID: 9605451)
Obstet Gynecol Int. 2013;2013:528158. (PMID: 23606847)
Am J Perinatol. 1993 Sep;10(5):341-7. (PMID: 8240589)
J Obstet Gynaecol Res. 2013 Aug;39(8):1293-300. (PMID: 23800290)
Acta Obstet Gynecol Scand. 2012 Jun;91(6):744-9. (PMID: 22375688)
Am J Perinatol. 1996 Oct;13(7):419-22. (PMID: 8960611)
Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):32-7. (PMID: 18243484)
J Reprod Med. 1996 Apr;41(4):235-8. (PMID: 8728074)
Clin Exp Obstet Gynecol. 1981;8(1):1-5. (PMID: 7307264)
BJOG. 2006 Dec;113 Suppl 3:17-42. (PMID: 17206962)
J Matern Fetal Neonatal Med. 2010 Jul;23(7):670-4. (PMID: 19883267)
Int Surg. 1995 Apr-Jun;80(2):170-4. (PMID: 8530237)
Am J Obstet Gynecol. 1992 Oct;167(4 Pt 1):1086-91. (PMID: 1415396)
J Perinat Med. 2001;29(1):31-5. (PMID: 11234614)
J Matern Fetal Neonatal Med. 2014 Jan;27(1):80-3. (PMID: 23672212)
Cochrane Database Syst Rev. 2013 May 31;(5):CD007873. (PMID: 23728668)
Clin Obstet Gynecol. 2009 Dec;52(4):597-610. (PMID: 20393412)
Am J Reprod Immunol. 2011 Oct;66(4):310-9. (PMID: 21410810)
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1746-9. (PMID: 22372642)
Obstet Gynecol. 1980 Nov;56(5):543-8. (PMID: 7001296)
Lancet. 2012 May 12;379(9828):1800-6. (PMID: 22475493)
- Publication Date:
Date Created: 20150929 Date Completed: 20160802 Latest Revision: 20231111
- Publication Date:
20231111
- Accession Number:
PMC4564585
- Accession Number:
10.1155/2015/185371
- Accession Number:
26413506
No Comments.